Literature DB >> 6576633

Urea-prostaglandin versus hypertonic saline for instillation abortion.

N J Binkin, K F Schulz, D A Grimes, W Cates.   

Abstract

Authorities have suggested use of a combination of hyperosmolar urea and low-dose prostaglandin F2 alpha as a second-trimester intra-amniotic abortifacient to avoid the disadvantages of hypertonic saline solution. To examine the safety and efficacy of urea-prostaglandin compared with the instillation of saline solution, we analyzed data from a prospective multicenter study conducted in the United States between 1975 and 1978. Both agents were highly effective in producing an abortion. However, urea-prostaglandin had a significantly lower rate of serious complications when compared with saline solution (1.03 versus 2.18 per 100 abortions; p less than 0.001). Urea-prostaglandin also had a significantly shorter induction-to-abortion time (14.2 versus 25.6 hours; p less than 0.001). Urea-prostaglandin, therefore, appears to be superior to hypertonic saline solution as an abortifacient.

Entities:  

Keywords:  Abortifacient Agents; Abortion History; Abortion, Drug Induced; Abortion, Induced; Age Factors; Biology; Bleeding; Cervical Effects; Endocrine System; Endometritis; Ethnic Groups; Evaluation; Family Planning; Fertility Control, Postconception; Ingredients And Chemicals; Laminaria Tents; Marital Status; Organic Chemicals--administraction and dosage; Organic Chemicals--complications; Physiology; Pregnancy History; Prostaglandins--administraction and dosage; Prostaglandins--complications; Saline Solution, Hypertonic--administraction and dosage; Saline Solution, Hypertonic--complications; Surgery

Mesh:

Substances:

Year:  1983        PMID: 6576633     DOI: 10.1016/0002-9378(83)90971-7

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  1 in total

1.  Lack of coagulation defects after the intraamniotic instillation of ethacridine (Rivanol) for second trimester abortion.

Authors:  F K Beller; R E Zimmermann; U H Winkler; D Seitzer; W Holzgreve
Journal:  Arch Gynecol Obstet       Date:  1988       Impact factor: 2.344

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.